
Solventum Corporation (SOLV) Stock Forecast & Price Target
Solventum Corporation (SOLV) Analyst Ratings
Bulls say
Solventum is a healthcare company with a strong track record of performance and growth in all business segments, supporting a Buy rating and a target price of $89. While the company has a potential for higher growth and has implemented changes to support margins and growth, its lower growth profile compared to peers may warrant a lower price-to-earnings multiple. Potential risks include challenges in establishing itself as a standalone company and potential selling pressure from institutional investors.
Bears say
Solventum is a healthcare company that operates in the competitive and highly regulated medical technology sector, with its three segments MedSurg, Dental Solutions, and Health Information Systems contributing to its majority revenue from the United States. While SOLV has maintained its revenue and operating margin outlook for 2026, timing delays and tailwinds may hinder its performance. Furthermore, SOLV's lower growth profile and tougher comps in FY26 compared to FY25 may impact its stock price. Risks to SOLV's ability to achieve its financial targets include potential decreases in global healthcare spending, competitive pressure, and new regulatory requirements from the FDA.
This aggregate rating is based on analysts' research of Solventum Corporation and is not a guaranteed prediction by Public.com or investment advice.
Solventum Corporation (SOLV) Analyst Forecast & Price Prediction
Start investing in Solventum Corporation (SOLV)
Order type
Buy in
Order amount
Est. shares
0 shares